Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Baylor Collaborate on Customized CGH Microarrays

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized comparative genomics hybridization microarrays to researchers.

Baylor has designed six new microarrays that combined with Agilent's microarray manufacturing capabilities will "enable advanced discoveries in cancer and cytogenetics research," Agilent said.

"Originally focused on microdeletions and microduplications, our current designs have been continually improved over the past 10 years and are now highly robust, with the ability to detect exon-level deletions and duplications," Brandon Perthuis, director of business development at the BCM Medical Genetic Laboratories, said in a statement. "Our exon array targets approximately 1,700 genes and includes probes used for SNP analysis for the detection" of absence of heterozygosity and uniparental disomy.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.